PDCD1 and hepatocellular carcinoma: The novel therapeutic advances with several small molecules kinase inhibitors and immunotherapy, such as programmed death-ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway, may likely change the treatment scenario of HCC (2, 3).